Pricing Panacea Or PR Victory? Expedited US ANDAs May Have Limited Impact
This article was originally published in PharmAsia News
In theory, reviewing US generic applications faster should speed competition; in practice, the FDA's new policy likely won't make too much difference.
You may also be interested in...
Investigators should plan to find the vital status of discontinued patients, guidances states. Participants need frequent reminders to complete PRO instruments, agency recommends.
Talks between US FDA and industry to extend the generic drug and prescription drug user fee programs may last into 2021.
US FDA officials fear comparator arms would be unwieldy for ongoing trials as they consider alternative methods to measure efficacy if placebo controls can't be maintained for the studies of other candidate vaccines once a product is on the market.